Latest News
October 1, 2024
Sheba Medical Center, ARC & Mana.bio Announce Partnership to Revolutionize RNA Delivery for Cancer & Autoimmune Diseases
Mana.bio announces a strategic partnership with Sheba Medical Center, ARC to advance RNA therapies for cancer and autoimmune diseases, leveraging AI-driven LNP technology.
May 14, 2024
Raising Biotech podcast: Mana.bio and programmable lipid nanoparticles with CEO Yogev Debbi and RNA expert Dr Barry Ticho
Host Surani Fernando speaks with our CEO Yogev Debbi and fully explores our multi-layered start-up story including our origin, lab research and the challenges of launching the organization from stealth in October 2023 in the midst of the attacks on Israel.
February 28, 2024
Mana.bio partners with Ginkgo Bioworks to add delivery capabilities as part of its Technology Network Platform launch
Mana joins the Ginkgo Technology Network, leveraging integrated R&D capabilities alongside over 25 partners to drive innovation in AI, genetic medicines, biologics, and manufacturing, enhancing collaborative efforts and accelerating advancements in these fields.
October 10, 2023
Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver
One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles used to carry mRNA can be injected into the arm for vaccines or infused into the blood to shuttle genetic medicines to the liver. But delivering the molecules to other cells or organs remains a challenge.
March 8, 2023
The Decade of RNA Delivery – Beyond the Liver
With the opportunity to treat spades of infectious diseases, cancers and single gene disorders, there is enormous potential in RNA therapeutics. To realize it, however, researchers will need to optimize delivery to on-target cells, minimize exposure to off-target cells and move beyond the liver.
January 1, 2023
Tech Founders, Don’t Be Afraid of Bio
Starting a TechBio company is a rewarding challenge. In this episode Yogev Debbi, Co-founder and CEO at Mana.bio enjoys discussing it with Omri Amirav-Drory from NFX, his co-founder from their first TechBio company Genome Compiler and now an investor at Mana.bio where we're disrupting Drug Delivery using ML/AI.
June 21, 2022
Mana.bio integrates CAS chemical substance data into its novel drug delivery AI platform
An agreement to embed chemical substance data from the CAS Content CollectionTM directly into the Mana.bio AI data acquisition workflow via an application programmable interface (API). This collaboration will enrich Mana.bio’s proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.